Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A user in their mid-30s experienced unexpected hairline regrowth after starting a new supplement stack, despite being on a regimen of finasteride, minoxidil, and Nizoral for over four years. The new supplements include Tongkat Ali, Fadogia Agrestis, Panax Red Ginseng, Vitamin B1, Vitamin D3, Zinc Picolinate, Magnesium Glycinate, Maca, and L-Citrulline.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Pregnancy can temporarily reverse hair loss in women, but attempts to mimic pregnancy hormones with treatments like contraceptive pills, spironolactone, estradiol, progesterone, finasteride, and minoxidil have been ineffective. The discussion highlights the need for research into the hormonal mechanisms of pregnancy that affect hair regrowth.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.

The post discusses using Sandalore as a potential hair loss treatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.

Bimatoprost and latanoprost are being considered for scalp hair growth, with concerns about side effects like skin darkening and fat loss. A user warns about potential chemical burns from latanoprost.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

The conversation is about using Latanoprost 0.01% solution for hair loss and seeking success stories. It mentions that Latanoprost works differently from Minoxidil, Finasteride, and RU58841.

User DeadRay9 reports good progress on finasteride and ketoconazole, with irregular microneedling. They take 1.25mg finasteride, experienced increased libido, and saw improvements at 3-5 months.

The conversation is about using RU58841 for hair loss treatment, specifically mixing it with minoxidil without propylene glycol due to an allergy. The user is considering starting with a lower concentration of RU58841 and making smaller batches to maintain efficacy.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

The user started using oral minoxidil and estradiol in August 2025, added finasteride in December, and experienced significant hair shedding in February/March. They switched to estradiol injections and are considering their hair washing routine, while another user suggested consulting a dermatologist and possibly trying dutasteride.

Hair regrowth was achieved using minoxidil, nizoral, alfatrodial, and pyrilutamide after finasteride caused side effects. The user recommends this combination for those who can't tolerate 5AR inhibitors, stressing consistent use.

The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.